Clyde Hosein
About Clyde Hosein
Independent Class III director (age 65 as of record date) at Credo (CRDO) since April 2024; chairs the Audit Committee and serves on the Compensation Committee. He is an “audit committee financial expert” with 25+ years as CFO of public technology companies; education includes a B.S. in Industrial Engineering (Polytechnic Institute of NYU) and an MBA in Finance & International Business (NYU Stern) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| SambaNova Systems | President & COO | Since Apr 2025 | Executive operator in AI infrastructure; governance time commitment consideration |
| AliveCor Inc. | Chief Financial Officer | Mar 2021 – Apr 2023 | CFO oversight in med-tech AI/ECG |
| Automation Anywhere, Inc. | Chief Financial Officer | Dec 2017 – Mar 2021 | Enterprise software/RPA finance leader |
| RingCentral, Inc. | EVP & Chief Financial Officer | Aug 2013 – May 2017 | Public SaaS CFO experience |
| Marvell Technology Group Ltd. | CFO & COO (senior roles) | Not disclosed | Semiconductor operator and finance |
| Integrated Device Technology, Inc. | Vice President & CFO | Not disclosed | Semiconductor CFO |
| Candescent Technologies | Chief Financial Officer | Not disclosed | CFO role |
| IBM Corporation | Engineering & Finance roles | 14 years (early career) | Foundational engineering/finance experience |
External Roles
| Organization | Role | Tenure | Committees/Notes |
|---|---|---|---|
| Dentsply Sirona Inc. (XRAY) | Director | Since Sep 2020 | One of the largest professional dental products companies |
| Wolfspeed (WOLF) | Director | Dec 2005 – Dec 2024 | Silicon carbide leader; tenure concluded Dec 2024 |
| Myasthenia Gravis Foundation of America | Board member | Not disclosed | Non-profit patient advocacy |
Board Governance
- Committee assignments: Audit (Chair), Compensation (Member); not on NCG .
- Independence: Board determined Hosein is independent; designated “audit committee financial expert” .
- Attendance: Board held 4 meetings in fiscal 2025; each current director attended ≥75% of Board and applicable committee meetings; Audit held 8, Compensation 4, NCG 5 meetings .
- Lead Independent Director: Sylvia Acevedo .
- Audit Committee report: Signed by Hosein as Chair; recommended inclusion of audited financials and appointment of Ernst & Young LLP for FY ending May 2, 2026, subject to shareholder ratification .
Fixed Compensation
| Component | Amount / Policy | Notes |
|---|---|---|
| Board cash retainer | $50,000 per year | Paid quarterly in arrears |
| Audit Committee Chair retainer | $20,000 per year | |
| Audit Committee member retainer | $10,000 per year | |
| Compensation Committee member retainer | $7,500 per year | |
| NCG Chair/member retainers | $10,000 / $5,000 per year | Not applicable to Hosein based on current assignments |
| FY2025 cash fees (Hosein) | $83,796 | Actual cash earned in fiscal 2025 |
Performance Compensation
| Equity Award | Grant Value | Shares/Calc | Vesting | Notes |
|---|---|---|---|---|
| Initial RSU (upon election Apr 3, 2024) | $350,000 | Shares calculated using trailing 30-day average price | Vests in 3 equal annual installments beginning 1-year from appointment | Director service required for vesting |
| Annual RSU (post 2024 AGM) | $175,000 | 175,000 ÷ $39.70 closing price following 2024 AGM | Vests at earlier of 1-year or next AGM, subject to service | Annual program for continuing non-employee directors |
| Outstanding RSUs (as of FY2025 end) | 4,408 units (Hosein) | — | Unvested at FY-end (timing per above) |
Performance metric framework for director pay:
| Metric Category | Detail |
|---|---|
| Performance-linked metrics in director compensation | None disclosed; director RSUs are time-based vesting, not tied to revenue/EBITDA/TSR metrics |
Other Directorships & Interlocks
| Company | Type | Role | Potential Interlock/Conflict |
|---|---|---|---|
| Dentsply Sirona (XRAY) | Public | Director | No Credo-related transaction disclosed |
| Wolfspeed (WOLF) | Public | Director (ended Dec 2024) | No Credo-related transaction disclosed |
| SambaNova Systems | Private | President & COO | Operating role concurrent with Credo directorship; time-commitment watch item; no related-party transactions disclosed |
- Compensation Committee interlocks: None among members for fiscal 2025 (Hosein is a member) .
- Related party transactions: Company states none meeting SEC thresholds other than disclosed compensation; registration rights described generally; no Hosein-specific related-party transactions disclosed .
Expertise & Qualifications
- Financial expert/audit chair experience; extensive CFO track record at public tech companies .
- Semiconductor industry knowledge (Marvell, IDT, Wolfspeed board tenure) .
- Executive leadership in AI infrastructure (SambaNova) .
- Education: B.S. Industrial Engineering (Polytechnic Institute of NYU); MBA Finance & International Business (NYU Stern) .
Equity Ownership
| Item | Amount | Notes |
|---|---|---|
| Shares beneficially owned | 3,451 | As of July 31, 2025 |
| Ownership % of outstanding | <1% (“*”) | Based on 172,914,100 shares outstanding |
| Outstanding RSUs | 4,408 units | As of FY2025 end |
| Pledged shares | Prohibited by anti-pledging policy | Company policy prohibits hedging and pledging for directors |
| Options | Not disclosed | No director option awards disclosed in FY2025 section |
| Stock ownership guideline | ≥4× annual cash retainer for directors; 4-year compliance window | For Hosein (appointed Apr 3, 2024), guideline deadline by Apr 2028 |
Governance Assessment
-
Strengths
- Audit Committee Chair with “financial expert” designation; clear engagement evidenced by Audit Committee report and oversight of auditor independence .
- Independence affirmed; robust anti-hedging/pledging policy and newly adopted stock ownership guidelines for directors (4× cash retainer within 4 years) .
- Attendance threshold met (≥75%) alongside active committee cadence (Audit 8; Compensation 4) indicating reasonable engagement .
- Director compensation structure balanced: modest cash fees plus annual/time-based RSUs; no meeting fees or option repricing disclosed .
-
Watch items
- Low current beneficial ownership (3,451 shares; <1%) with alignment building via RSUs; monitor progress toward stock ownership guideline by April 2028 .
- Concurrent operating role (President & COO at SambaNova Systems) may impact time availability; continue to monitor attendance and committee outputs .
- No director-specific performance metrics in equity grants; alignment relies on time-based RSU exposure rather than performance vesting .
-
Red flags
- None disclosed regarding related-party transactions, hedging/pledging, legal proceedings, or compensation committee interlocks; say-on-pay support strong at 88% for FY2024 for executives, with governance enhancements subsequently adopted (though executive-focused) .